Role of notch signaling in colorectal cancer

Carcinogenesis

Volumn 30, Issue 12, 2009, Pages 1979-1986

  Qiao, Liang ^a,b   Wong, Benjamin C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BEVACIZUMAB; CYCLIN D1; DIBENZAZEPINE DERIVATIVE; EPIDERMAL GROWTH FACTOR; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR HES 1; VASCULOTROPIN; WNT PROTEIN; LIGAND;

ANGIOGENESIS; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL TUMOR; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 73949094187     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp236     Document Type: Review

References (155)

1. Artavanis-Tsakonas, S. et al. (1999) Notch signaling: cell fate control and signal integration in development. Science, 284, 770-776.
2. Gray, G.E. et al. (1999) Human ligands of the Notch receptor. Am. J. Surg. Pathol., 154, 785-794.
3. Tanimizu, N. et al. (2004) Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J. Cell Sci., 117, 3165-3174.
4. Nijjar, S. et al. (2001) Notch receptor expression in adult human liver: a possible role in bile duct formation and hepatic neovascularisation. Hepatology, 34, 1184-1192.
5. Meng, R.D. et al. (2009) γ-Secretase inhibitors abrogate oxaliplatininduced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res., 69, 573-582.
6. Lai, E.C. (2004) Notch signaling: control of cell communication and cell fate. Development, 131, 965-973.
7. Blaumueller, C.M. et al. (1997) Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell, 90, 281-291.
8. Zhang, Y. et al. (2006) Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int. J. Cancer, 119, 2071-2077.
9. Yao, J. et al. (2007) Notch1 induces cell cycle arrest and apoptosis in human cervical cancer cells: involvement of nuclear factor j B inhibition. Int. J. Gynecol. Cancer, 17, 502-510.
10. + hematopoietic progenitor cells. Stem Cells, 25, 203-210.
11. Garber, K. (2007) Arrested development? Notch emerges as new cancer drug target. J. Natl Cancer Inst., 99, 1284-1285.
12. Schroeter, E.H. et al. (1998) Notch 1 signaling requires ligand-induced proteolytic release of intracellular domain. Nature, 393, 382-386.
13. Terris, B. et al. (2002) Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am. J. Pathol., 160, 1745-1754.
14. Miyamoto, Y. et al. (2003) Notch mediates TGFa-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell, 3, 565-576.
15. Wang, Z. et al. (2006) Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-jB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res., 66, 2778-2784.
16. Kimura, K. et al. (2007) Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci., 98, 155-162.
17. Reedijk, M. et al. (2005) High-level co-expression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res., 65, 8530-8537.
18. Stylianou, S. et al. (2006) Aberrant activation of notch signaling in human breast cancer. Cancer Res., 66, 1517-1525.
19. Santagata, S. et al. (2004) JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res., 64, 6854-6857.
20. Gao, J. et al. (2007) Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 356, 341-347.
21. Qi, R. et al. (2003) Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res., 63, 8323-8329.
22. Zagouras, P. et al. (1995) Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc. Natl Acad. Sci. USA, 92, 6414-6418.
23. Weijzen, S. et al. (2003) HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J. Cell. Physiol., 194, 356-362.
24. Ramdass, B. et al. (2007) Co-expression of Notch1 and NF-jB signaling pathway components in human cervical cancer progression. Gynecol. Oncol., 104, 352-361.
25. Baliko, F. et al. (2007) Inhibition of Notch signaling induces neural differentiation in Ewing sarcoma. Am. J. Pathol., 170, 1686-1694.
26. Curry, C.L. et al. (2007) Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-jB signaling. Mol. Cancer Ther., 6, 1983-1992.
27. Konishi, J. et al. (2007) γ-Secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res., 67, 8051-8057.
28. Hopfer, O. et al. (2005) The Notch pathway in ovarian carcinomas and adenomas. Br. J. Cancer, 93, 709-718.
29. Jundt, F. et al. (2002) Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood, 99, 3398-3403.
30. Sjölund, J. et al. (2008) Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J. Clin. Invest., 118, 217-228.
31. Sureban, S.M. et al. (2008) Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology, 134, 1448-1458.
32. Akiyoshi, T. et al. (2008) γ-Secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology, 134, 131-144.
33. Pear, W.S. et al. (1996) Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med., 183, 2283-2291.
34. Farnie, G. et al. (2007) Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J. Natl Cancer Inst., 99, 616-627.
35. Farnie, G. et al. (2007) Mammary stem cells and breast cancer-role of Notch signaling. Stem Cell Rev., 3, 169-175.
36. Joutel, A. et al. (1998) Notch signaling pathway and human diseases. Semin. Cell Dev. Biol., 9, 619-625.
37. Miele, L. et al. (1999) Arbiter of differentiation and death: Notch signaling meets apoptosis. J. Cell. Physiol., 181, 393-409.
38. Nickoloff, B.J. et al. (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene, 22, 6598-6608.
39. Katoh, M. et al. (2007) Notch signaling in gastrointestinal tract [review]. Int. J. Oncol., 30, 247-251.
40. Radtke, F. et al. (2006) From gut homeostasis to cancer. Curr. Mol. Med., 6, 275-289.
41. Fre, S. et al. (2005) Notch signals control the fate of immature progenitor cells in the intestine. Nature, 435, 964-968.
42. van de Wetering, M. et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell, 111, 241-250.
43. Riccio, O. et al. (2008) Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep., 9, 377-383.
44. Zheng, H. et al. (2009) KLF4 gene expression is inhibited by the notch signaling pathway that controls goblet cell differentiation in mouse gastrointestinal tract. Am. J. Physiol. Gastrointest. Liver Physiol., 296, G490-G498.
45. van Es, J.H. et al. (2005) Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature, 435, 959-963.
46. Schröder, N. et al. (2002) Expression of Notch pathway components in fetal and adult mouse small intestine. Gene Expr. Patterns, 2, 247-250.
47. Sander, G.R. et al. (2004) Expression of notch receptors and ligands in the adult gut. J. Histochem. Cytochem., 52, 509-516.
48. Kosinski, C. et al. (2007) Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc. Natl Acad. Sci. USA, 104, 15418-15423.
49. Jensen, J. et al. (2000) Control of endodermal endocrine development by Hes-1. Nat. Genet., 24, 36-44.
50. Stanger, B.Z. et al. (2005) Direct regulation of intestinal fate by Notch. Proc. Natl Acad. Sci. USA, 102, 12443-12448.
51. van Es, J.H. et al. (2005) Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol. Med., 11, 496-502.
52. Okamoto, R. et al. (2009) Requirement of Notch activation during regeneration of the intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol., 296, G23-G35.
53. Suzuki, K. et al. (2005) Hes1-deficient mice show precocious differentiation of Paneth cells in the small intestine. Biochem. Biophys. Res. Commun., 328, 348-352.
54. Fre, S. et al. (2009) Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc. Natl Acad. Sci. USA, 106, 6309-6314.
55. Rodilla, V. et al. (2009) Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc. Natl Acad. Sci. USA, 106, 6315-6320.
56. Gersemann, M. et al. (2009) Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation, 77, 84-94.
57. Leow, C.C. et al. (2004) Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. Cancer Res., 64, 6050-6057.
58. Fernandez-Majada, V. et al. (2007) Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc. Natl Acad. Sci. USA, 104, 276-281.
59. Reedijk, M. et al. (2008) Activation of Notch signaling in human colon adenocarcinoma. Int. J. Oncol., 33, 1223-1239.
60. Veenendaal, L.M. et al. (2008) Differential Notch and TGF-b signaling in primary colorectal tumors and their corresponding metastases. Cell. Oncol., 30, 1-11.
61. Shih, I.e.M. et al. (2007) Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res., 67, 1879-1882.
62. Rangarajan, A. et al. (2001) Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J., 20, 3427-3436.
63. Morrison, S.J. et al. (2000) Transient Notch activation initiates an irreversible switch from neurogenesis to gliogenesis by neural crest stem cells. Cell, 101, 499-510.
64. Robey, E. et al. (1996) An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell, 87, 483-492.
65. Talora, C. et al. (2002) Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev., 16, 2252-2263.
66. Harper, J.A. et al. (2003) Notch signaling in development and disease. Clin. Genet., 64, 461-472.
67. Miele, L. et al. (2006) NOTCH signaling as a novel cancer therapeutic target. Curr. Cancer Drug Targets, 6, 313-323.
68. Roy, M. et al. (2007) The multifaceted role of Notch in cancer. Curr. Opin. Genet. Dev., 17, 52-59.
69. Ghaleb, A.M. et al. (2008) Notch inhibits expression of the Krüppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol. Cancer Res., 6, 1920-1927.
70. Okano, H. et al. (2002) Musashi: a translational regulator of cell fate. J. Cell Sci., 115, 1355-1359.
71. Alves-Guerra, M.C. et al. (2007) Mastermind-like 1 is a specific coactivator of b-catenin transcription activation and is essential for colon carcinoma cell survival. Cancer Res., 67, 8690-8698.
72. Garber, K. (2007) Targeting vessel abnormalization in cancer. J. Natl Cancer Inst., 99, 991-992, 995.
73. Li, J.L. et al. (2007) Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res., 67, 11244-11253.
74. O'Neil, J. et al. (2007) FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med., 204, 1813-1824.
75. Parsons, D.W. et al. (2005) Colorectal cancer: mutations in a signaling pathway. Nature, 436, 792.
76. Nair, P. et al. (2003) Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3K-PKB/Akt-dependent pathway. J. Virol., 77, 7106-7112.
77. Sade, H. et al. (2004) The anti-apoptotic effect of Notch-1 requires p56lckdependent, Akt/PKB-mediated signaling in T cells. J. Biol. Chem., 279, 2937-2944.
78. Smith, D.R. et al. (1993) Over-expression of the c-myc protooncogene in colorectal carcinoma. Br. J. Cancer, 68, 407-413.
79. Shin, D.M. et al. (2008) NOTCH is part of the transcriptional network regulating cell growth and survival in mouse plasmacytomas. Cancer Res., 68, 9202-9211.
80. Weng, A.P. et al. (2006) c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev., 20, 2096-2109.
81. Palomero, T. et al. (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA, 103, 18261-18266.
82. Efstratiadis, A. et al. (2007) Notch, Myc and breast cancer. Cell Cycle, 6, 418-429.
83. Ronchini, C. et al. (2001) Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol. Cell. Biol., 21, 5925-5934.
84. McKenna, W.G. et al. (2003) Signaling inhibition with radiation in colorectal cancer: clinical trials. Semin. Oncol., 30, 56-67.
85. Qiao, L. et al. (2009) Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Updat., 12, 55-64.
86. O'Dwyer, P.J. et al. (2002) Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin. Oncol., 29, 10-17.
87. Macarulla, T. et al. (2006) Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer. Onkologie, 29, 99-105.
88. Karameris, A. et al. (1993) Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol. Res. Pract., 189, 133-137.
89. Dai, J. et al. (2009) Cross-talk between Notch and EGFR signaling in human breast cancer cells. Cancer Invest., 5, 533-540.
90. Purow, B.W. et al. (2008) Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis, 29, 918-925.
91. Derdak, Z. et al. (2006) Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-jB activation and oxidative stress. Carcinogenesis, 27, 956-961.
92. Dolcet, X. et al. (2005) NF-jB in development and progression of human cancer. Virchows Arch., 446, 475-482.
93. Aranha, M.M. et al. (2007) NF-jB and apoptosis in colorectal tumourigenesis. Eur. J. Clin. Invest., 37, 416-424.
94. Oswald, F. et al. (1998) NF-jB2 is a putative target gene of activated Notch-1 via RBP-Jj. Mol. Cell. Biol., 18, 2077-2088.
95. Nickoloff, B.J. et al. (2002) Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-jB and PPARc. Cell Death Differ., 9, 842-855.
96. Wang, J. et al. (2001) Human Notch-1 inhibits NF-jB activity in the nucleus through a direct interaction involving a novel domain. J. Immunol., 167, 289-295.
97. Shin, H.M. et al. (2006) Notch1 augments NF-jB activity by facilitating its nuclear retention. EMBO J., 25, 129-138.
98. Jang, M.S. et al. (2004) Notch-1 regulates cell death independently of differentiation in murine erythroleukemia cells through multiple apoptosis and cell cycle pathways. J. Cell. Physiol., 199, 418-433.
99. Ghaleb, A.M. et al. (2007) Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res., 67, 7147-7154.
100. Levy, L. et al. (2006) Alterations in components of the TGF-b superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev., 17, 41-58.
101. Sun, Y. et al. (2005) Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-b signaling. Oncogene, 24, 5365-5374.
102. Niimi, H. et al. (2007) Notch signaling is necessary for epithelial growth arrest by TGF-b. J. Cell Biol., 176, 695-707.
103. Galizia, G. et al. (2004) Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin. Cancer Res., 10, 3490-3499.
104. Bergers, G. et al. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 3, 401-410.
105. Achen, M.G. et al. (1998) The vascular endothelial growth factor family; proteins which guide the development of the vasculature. Int. J. Exp. Pathol., 79, 255-265.
106. Takahashi, Y. et al. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res., 55, 3964-3968.
107. Bendardaf, R. et al. (2008) VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res., 28, 865-870.
108. Hurwitz, H. et al. (2004) Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 350, 2335-2342.
109. Zeng, Q. et al. (2005) Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell, 8, 13-23.
110. Leong, K.G. et al. (2006) Recent insights into the role of Notch signaling in tumorigenesis. Blood, 107, 2223-2233.
111. Roca, C. et al. (2007) Regulation of vascular morphogenesis by Notch signaling. Genes Dev., 21, 2511-2524.
112. Koch, U. et al. (2007) Notch and cancer: a double-edged sword. Cell. Mol. Life Sci., 64, 2746-2762.
113. Mailhos, C. et al. (2001) Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation, 69, 135-144.
114. Alva, J.A. et al. (2004) Notch signaling in vascular morphogenesis. Curr. Opin. Hematol., 11, 278-283.
115. Claxton, S. et al. (2004) Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr. Patterns, 5, 123-127.
116. Dufraine, J. et al. (2008) Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene, 27, 5132-5137.
117. Benedito, R. et al. (2009) The Notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell, 137, 1124-1135.
118. Gale, N.W. et al. (2004) Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl Acad. Sci. USA, 101, 15949-15954.
119. Krebs, L.T. et al. (2004) Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev., 18, 2469-2473.
120. High, F.A. et al. (2008) The multifaceted role of Notch in cardiac development and disease. Nat. Rev. Genet., 9, 49-61.
121. Xue, Y. et al. (1999) Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum. Mol. Genet., 8, 723-730.
122. Krebs, L.T. et al. (2000) Notch signaling is essential for vascular morphogenesis in mice. Genes Dev., 14, 1343-1352.
123. Uyttendaele, H. et al. (2001) Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc. Natl Acad. Sci. USA, 98, 5643-5648.
124. Suchting, S. et al. (2007) The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl Acad. Sci. USA, 104, 3225-3230.
125. Williams, C.K. et al. (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood, 107, 931-939.
126. Patel, N.S. et al. (2006) Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res., 12, 4836-4844.
127. Patel, N.S. et al. (2005) Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res., 65, 8690-8697.
128. Noguera-Troise, I. et al. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature, 444, 1032-1037.
129. Funahashi, Y. et al. (2008) A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res., 68, 4727-4735.
130. Johnston, D.A. et al. (2009) TNF induction of Jagged-1 in endothelial cells is NF-jB-dependent. Gene, 435, 36-44.
131. Potten, C.S. et al. (2003) Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation, 71, 28-41.
132. Brabletz, S. et al. (2009) Gastrointestinal stem cells in development and cancer. J. Pathol., 217, 307-317.
133. O'Brien, C.A. et al. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106-110.
134. Ricci-Vitiani, L. et al. (2007) Identification and expansion of human colon cancer-initiating cells. Nature, 445, 111-115.
135. Dalerba, P. et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA, 104, 10158-10163.
136. Fan, X. et al. (2006) Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res., 66, 7445-7452.
137. Ang, B.T. et al. (2007) Cancer stem cell: target for anti-cancer therapy. FASEB J., 21, 3777-3785.
138. Kayahara, T. et al. (2003) Candidate markers for stem and early progenitor cells, Musashi-1 and Hes1, are expressed in crypt base columnar cells of mouse small intestine. FEBS Lett., 535, 131-135.
139. de Lau, W. et al. (2007) WNT signaling in the normal intestine and colorectal cancer. Front. Biosci., 12, 471-491.
140. Qiao, L. et al. (2008) Loss of XIAP sensitizes colon cancer cells to PPARc independent antitumor effects of troglitazone and 15-PGJ2. Cancer Lett., 268, 260-271.
141. Koeffler, H.P. (2003) Peroxisome proliferator-activated receptor c and cancers. Clin. Cancer Res., 9, 1-9.
142. Panigrahy, D. et al. (2003) Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin. Invest. Drugs, 12, 1925-1937.
143. Brockman, J.A. et al. (1998) Activation of PPARc leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology, 115, 1049-1055.
144. Qiao, L. et al. (2009) Down-regulation of X-linked inhibitor of apoptosis synergistically enhanced peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition in colon cancer. Mol. Cancer Ther., 7, 2203-2211.
145. Dai, Y. et al. (2008) Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. Int. J. Cancer, 122, 2858-2863.
146. Dai, Y. et al. (2007) Activation of PPARc and inhibition of XIAP in human cancer cells: synergistic effects on cell proliferation, apoptosis, and tumorigenesis. Gastroenterology, 132, A425.
147. Elias, P.M. (1996) The stratum corneum revisited. J. Dermatol., 23, 756-768.
148. Garces, C. et al. (1997) Notch-1 controls the expression of fatty acid activated transcription factors and is required for adipogenesis. J. Biol. Chem., 272, 29729-29734.
149. Ross, D.A. et al. (2004) Dual roles for the Notch target gene Hes-1 in the differentiation of 3T3-L1 preadipocytes. Mol. Cell. Biol., 24, 3505-3513.
150. Staal, F.J.T. et al. (2008) Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia. Haematologica, 93, 493-497.
151. Grosveld, G.C. (2009) γ-secretase inhibitors: Notch so bad. Nat. Med., 15, 20-21.
152. Wong, G.T. et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem., 279, 12876-12882.
153. Milano, J. et al. (2004) Modulation of notch processing by gammasecretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci., 82, 341-358.
154. Barten, D.M. et al. (2006) γ-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R. D., 7, 87-97.
155. Deangelo, D.J. et al. (2006) A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias [abstract]. ASCO Annu. Meet. Proc., 24, 6585.